Biopharmaceutical company CorMedix Inc. (NASDAQ: CRMD) reported a sharp increase in revenues for the fourth quarter of fiscal 2025, primarily driven by continued utilization of its DefenCath by outpatient dialysis customers.
The New Jersey-headquartered company, which is focused on developing therapeutic products for life-threatening diseases, posted total revenues of $128.6 million for the final three months of FY25, versus $31.2 million in the year-ago quarter. Sales of DefenCath, the company’s FDA-approved antimicrobial catheter lock solution, contributed $91.2 million of revenue.
Net Income was $14.02 million in the fourth quarter, slightly higher than $13.5 million reported in Q4 2024. However, on a per-share basis, earnings declined to $0.16 in the fourth quarter from $0.20 in the prior-year period.
Adjusted EBITDA, which excludes non-cash items such as depreciation, amortization, stock-based compensation, and interest, totaled $77.2 million in Q4, compared to $15.3 million in the year-ago quarter.
Management reaffirmed its previously issued 2026 guidance and continues to expect full-year net revenue to be between $300 million and $320 million. The guidance for FY26 adjusted EBITDA has been reiterated in the $100-125 million range. Last month, the company approved a buyback program to repurchase up to $75 million of its outstanding common stock.
Joe Todisco, CorMedix’s CEO, said, “With the announcement of our share repurchase program and multiple near-term milestones on the horizon, most notably the Rezzayo ReSPECT phase III data, CorMedix is focused on driving business growth and shareholder value over the year ahead.”
The post CorMedix (CRMD) reports higher Q4 2025 net profit on strong revenue growth first appeared on AlphaStreet News.
